Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Atypical Teratoid/Rhabdoid Tumor: early-phase trial registry
4 of 10 indexed Atypical Teratoid/Rhabdoid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Atypical Teratoid/Rhabdoid Tumor: 10 US clinical trials tracked, 4 recruiting.
Atypical Teratoid/Rhabdoid Tumor is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Seattle Children's Hospital, running 2 of these trials.
Enrollment posture brief
Registry condition atypical-teratoidrhabdoid-tumor
OPEN 4 | RECR 40% | LATE 0 | EARLY 10 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)
Atypical Teratoid/Rhabdoid Tumor lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Atypical Teratoid/Rhabdoid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Atypical Teratoid/Rhabdoid Tumor is recruiting below its size-band peers.
4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Atypical Teratoid/Rhabdoid Tumor research.
Seattle Children's Hospital accounts for 2 of 10 trials (20%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Atypical Teratoid/Rhabdoid Tumor trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 10 trials that report a genuine target (sentinel values excluded). 8 of those (80%) plan for fewer than 100 participants.
-
Atypical Teratoid/Rhabdoid Tumor research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
NCT06465199
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Seattle Children's Hospital
NCT04185038
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Susan Chi, MD
NCT05407441
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
NCT05835687
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
St. Jude Children's Research Hospital
NCT02114229
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
NCT05286801
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
Dana-Farber Cancer Institute
NCT04416568
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Seattle Children's Hospital
NCT03500991
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
Sabine Mueller, MD, PhD
NCT02962167
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
Emory University
NCT01331135
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Atypical Teratoid/Rhabdoid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Atypical Teratoid/Rhabdoid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Atypical Teratoid/Rhabdoid Tumor page
10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Atypical Teratoid/Rhabdoid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Seattle Children's Hospital sponsors the most Atypical Teratoid/Rhabdoid Tumor trials on record, review their full trial history before evaluating a specific study. See Seattle Children's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atypical Teratoid/Rhabdoid Tumor condition card totals 10 registered trials; most-linked intervention Ipilimumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.